Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics Inc. has achieved a significant milestone by receiving a $5 million payment from Roche, reflecting progress in the development of OpRegen for dry age-related macular degeneration, which indicates robust clinical execution and collaboration. The company’s pipeline showcases innovative therapies targeting various degenerative conditions, with OpRegen demonstrating potential breakthroughs in vision restoration compared to existing treatments, thus highlighting the promising efficacy of its approach. Additionally, the advancement of Lineage's ReSonance program into preclinical stages with minimal investment further underscores the company's capacity for strategic development and innovation within the biotechnology sector.

Bears say

Lineage Cell Therapeutics Inc. faces significant challenges in progressing its product pipeline due to the inherent risks associated with clinical trials, where failed or inconclusive results could severely hamper development efforts. Additionally, the company may struggle to secure sufficient funding necessary to advance its therapies, potentially stalling critical projects in its portfolio. The overall increased risk surrounding the regenerative medicine sector further complicates the financial outlook for Lineage, suggesting underlying instability in achieving future milestones.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.